FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W563603991> ?p ?o ?g. }

• W563603991 endingPage "10514" @default.
• W563603991 startingPage "10514" @default.
• W563603991 abstract "10514 Background: Neoadjuvant and adjuvant chemotherapy is now standard practice for patients who present with localized osteosarcoma. We present the long-term follow-up (>20years) for one of the original prospective randomized trials that compared adjuvant chemotherapy to no treatment in patients with high-grade operable osteosarcoma. Methods: The original study was performed at UCLA from 1981 to 1984. During this time, 59 patients with high-grade, operable, non-metastatic osteosarcoma were randomized to receive adjuvant chemotherapy (MSKCC T-10B protocol)(N=32; 24 men, 8 women, median age 15 yrs) vs. expectant management (N=27; 20 men, 7 women, median age 18 yrs). All patients received one neoadjuvant course of intra-arterial doxorubicin hydrochloride (90mg) and radiation (1750cGy). At a median follow-up of 2 years, there was a statistically significant improvement in both disease-free (55% vs. 20%, p<.01) and overall survival (80% vs. 48%, p<.01) for those who received immediate adjuvant chemotherapy. Upon recurrence, patients in the T-10B arm received salvage chemotherapy with doxorubicin hydrochloride and cisplatin while those in the expectant arm received the T-10B protocol. 27 years after the initiation of the trial, long-term follow-up was obtained on all patients. Results: Median follow-up time for survivors was 24 years. 18 patients in the adjuvant chemotherapy arm died of disease (DOD) while 14 have no evidence of disease (NED). 22 patients in the control arm DOD, 1 died of other causes and 4 have NED. The 5, 10, and 20 year disease specific survival (DSS) for the treatment arm (47%, 43%, 43% respectfully) was significantly better than that of the control arm (30%, 26%, 17% respectfully) (p=0.0254). Conclusions: Early administration of chemotherapy in patients with high-grade operable osteosarcoma provides a significant survival benefit that is maintained with long-term (>20 years) follow-up. These results support the idea that early systemic treatment offers the best opportunity to cure patients with this high-risk malignancy. No significant financial relationships to disclose." @default.
• W563603991 created "2016-06-24" @default.
• W563603991 creator A5005083505 @default.
• W563603991 creator A5022613511 @default.
• W563603991 creator A5025456475 @default.
• W563603991 creator A5031037291 @default.
• W563603991 creator A5044545947 @default.
• W563603991 creator A5079400415 @default.
• W563603991 creator A5090447737 @default.
• W563603991 date "2009-05-20" @default.
• W563603991 modified "2023-09-25" @default.
• W563603991 title "Long-term follow-up (>20 years) for one of the original randomized prospective trials evaluating adjuvant chemotherapy in patients with high-grade operable osteosarcoma" @default.
• W563603991 doi "https://doi.org/10.1200/jco.2009.27.15_suppl.10514" @default.
• W563603991 hasPublicationYear "2009" @default.
• W563603991 type Work @default.
• W563603991 sameAs 563603991 @default.
• W563603991 citedByCount "0" @default.
• W563603991 crossrefType "journal-article" @default.
• W563603991 hasAuthorship W563603991A5005083505 @default.
• W563603991 hasAuthorship W563603991A5022613511 @default.
• W563603991 hasAuthorship W563603991A5025456475 @default.
• W563603991 hasAuthorship W563603991A5031037291 @default.
• W563603991 hasAuthorship W563603991A5044545947 @default.
• W563603991 hasAuthorship W563603991A5079400415 @default.
• W563603991 hasAuthorship W563603991A5090447737 @default.
• W563603991 hasConcept C126322002 @default.
• W563603991 hasConcept C141071460 @default.
• W563603991 hasConcept C142724271 @default.
• W563603991 hasConcept C143998085 @default.
• W563603991 hasConcept C168563851 @default.
• W563603991 hasConcept C2776694085 @default.
• W563603991 hasConcept C2777760704 @default.
• W563603991 hasConcept C2777863537 @default.
• W563603991 hasConcept C71924100 @default.
• W563603991 hasConceptScore W563603991C126322002 @default.
• W563603991 hasConceptScore W563603991C141071460 @default.
• W563603991 hasConceptScore W563603991C142724271 @default.
• W563603991 hasConceptScore W563603991C143998085 @default.
• W563603991 hasConceptScore W563603991C168563851 @default.
• W563603991 hasConceptScore W563603991C2776694085 @default.
• W563603991 hasConceptScore W563603991C2777760704 @default.
• W563603991 hasConceptScore W563603991C2777863537 @default.
• W563603991 hasConceptScore W563603991C71924100 @default.
• W563603991 hasIssue "15_suppl" @default.
• W563603991 hasLocation W5636039911 @default.
• W563603991 hasOpenAccess W563603991 @default.
• W563603991 hasPrimaryLocation W5636039911 @default.
• W563603991 hasRelatedWork W1999523291 @default.
• W563603991 hasRelatedWork W2004361516 @default.
• W563603991 hasRelatedWork W2254989877 @default.
• W563603991 hasRelatedWork W2329218644 @default.
• W563603991 hasRelatedWork W2338510447 @default.
• W563603991 hasRelatedWork W2356313098 @default.
• W563603991 hasRelatedWork W2387957804 @default.
• W563603991 hasRelatedWork W2463659514 @default.
• W563603991 hasRelatedWork W3029632585 @default.
• W563603991 hasRelatedWork W3032727485 @default.
• W563603991 hasVolume "27" @default.
• W563603991 isParatext "false" @default.
• W563603991 isRetracted "false" @default.
• W563603991 magId "563603991" @default.
• W563603991 workType "article" @default.